close

Novartis expands Zolgensma® manufacturing capacity with approval of multi-product North Carolina facility

Novartis expands Zolgensma® manufacturing capacity with approval of multi-product North Carolina facility   The FDA has granted commercial licensure approval for Novartis' Durham, N.C. site, a multi-product gene therapy manufacturing facility. This approval allows the state-of-the-art, 170,000 square-foot facility to make, test and release commercial Zolgensma®, as well as produce…..